Abstract
The outcome of patients with advanced colorectal cancer has significantly improved in the past decade because of the development of new treatment strategies. The Dutch Colorectal Cancer Group (DCCG) is a national multidisciplinary clinical research group in The Netherlands. The 3 CAIRO studies of the DCCG address clinically relevant questions in patients with advanced colorectal cancer: the benefit of combination versus sequential therapy, targeting vascular endothelial growth factor and epidermal growth factor receptor, and the role of maintenance therapy. This article presents the outline of these studies and summarizes the current results.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Capecitabine
-
Cetuximab
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / pathology
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Disease Progression
-
Drug Administration Schedule
-
ErbB Receptors / drug effects
-
Fluorouracil / administration & dosage
-
Fluorouracil / analogs & derivatives
-
Humans
-
Neoplasm Staging
-
Netherlands
-
Organoplatinum Compounds / administration & dosage
-
Oxaliplatin
-
Receptors, Vascular Endothelial Growth Factor / drug effects
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Organoplatinum Compounds
-
Oxaliplatin
-
Deoxycytidine
-
Bevacizumab
-
Capecitabine
-
ErbB Receptors
-
Receptors, Vascular Endothelial Growth Factor
-
Cetuximab
-
Fluorouracil